



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Description:

Percutaneous tibial nerve stimulation (PTNS; also known as posterior tibial nerve stimulation) is an electrical neuromodulation technique used primarily for treating voiding dysfunction. Subcutaneous tibial nerve stimulation via an implantable peripheral neurostimulator is an alternate technique for treating urgency urinary incontinence associated with overactive bladder syndrome.

Voiding Dysfunction

Common causes of non-neurogenic voiding dysfunction are pelvic floor neuromuscular changes (e.g., from pregnancy, childbirth, surgery), inflammation, medication (e.g., diuretics, anticholinergics), obesity, and psychogenic factors. Overactive bladder is a non-neurogenic voiding dysfunction characterized by urinary frequency, urgency, urge incontinence, and nonobstructive retention.

Neurogenic bladder dysfunction is caused by neurologic damage in individuals with multiple sclerosis, spinal cord injury, detrusor hyperreflexia, or diabetes with peripheral nerve involvement. The symptoms include overflow incontinence, frequency, urgency, urge incontinence, and retention.

Treatment

Approaches to the treatment of incontinence differentiate between urge incontinence and stress incontinence. Conservative behavioral management such as lifestyle modification (e.g., dietary changes, weight reduction, fluid management, smoking cessation) along with pelvic floor exercises and bladder training are part of the initial treatment of overactive bladder symptoms and both types of incontinence. Pharmacotherapy is another option, and different medications target different symptoms. Some individuals experience mixed incontinence.

If behavioral therapies and pharmacotherapy are unsuccessful, percutaneous tibial nerve stimulation (PTNS), sacral nerve stimulation, or botulinum toxin may be recommended.

Individuals may be considered to have failed behavioral therapies following an appropriate duration of 8 to 12 weeks without meeting treatment goals.

Individuals may be considered to have failed pharmacologic therapies following 4 to 8 weeks of treatment without meeting treatment goals.

Annual evaluation by a physician may be performed to ensure efficacy is continuing for maintenance percutaneous tibial nerve stimulation treatments.

Percutaneous Tibial Nerve Stimulation

The current indication cleared by the U.S. Food and Drug Administration (FDA) for PTNS is overactive bladder and associated symptoms of urinary frequency, urinary urgency, and urge incontinence.

Altering the function of the posterior tibial nerve with PTNS is believed to improve voiding function and control. The mechanism of action is believed to be retrograde stimulation of the lumbosacral nerves (L4-S3) via the posterior tibial nerve located near the ankle. The lumbosacral nerves control the bladder detrusor and perineal floor.

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Administration of PTNS consists of inserting a needle above the medial malleolus into the posterior tibial nerve followed by the application of low-voltage (10 mA, 1-10 Hz frequency) electrical stimulation that produces sensory and motor responses as evidenced by a tickling sensation and plantarflexion or fanning of all toes. Noninvasive PTNS has also been delivered with transcutaneous or surface electrodes. The recommended course of treatment is an initial series of 12 weekly office-based treatments followed by an individualized maintenance treatment schedule.

Percutaneous tibial nerve stimulation is less invasive than traditional sacral nerve neuromodulation, which has been successfully used to treat urinary dysfunction but requires implantation of a permanent device. In sacral root neuromodulation, an implantable pulse generator that delivers controlled electrical impulses is attached to wire leads that connect to the sacral nerves, most commonly the S3 nerve root that modulates the neural pathways controlling bladder function.

Percutaneous tibial nerve stimulation has also been proposed as a treatment for non-neurogenic and neurogenic bladder syndromes and fecal incontinence.

Subcutaneous Tibial Nerve Stimulation

The current indication approved by the FDA for subcutaneous tibial nerve stimulation (STNS) is urgency urinary incontinence in individuals who are intolerant or who have had an inadequate response to more conservative treatments or who have undergone a successful trial of PTNS. STNS is administered through a coin-sized leadless battery-powered implant. STNS offers a less invasive alternative to traditional sacral nerve neuromodulation and offers a convenient delivery system for automated treatments without the need for chronic outpatient PTNS treatment sessions.

FDA cleared percutaneous tibial nerve stimulator devices include the Urgent® PC Neuromodulation System, NURO™ Neuromodulation System, Vivally® Wearable Neuromodulation System, and ZIDA Wearable Neuromodulation System. The eCoin® Peripheral Neurostimulator System is an FDA cleared subcutaneous tibial nerve stimulation implant.

Criteria:

- Percutaneous tibial nerve stimulation (PTNS) for an initial 12-week course for individuals with non-neurogenic urinary dysfunction including overactive bladder is considered **medically necessary** with documentation of **ALL** of the following:
 1. Failed behavioral therapy following an appropriate duration of 8 to 12 weeks without meeting treatment goals
 2. Failed pharmacologic therapy following 4 to 8 weeks of treatment without meeting treatment goals
- Maintenance therapy using monthly percutaneous tibial nerve stimulation for individuals following a 12-week initial course of percutaneous tibial nerve stimulation that resulted in improved urinary dysfunction meeting treatment goals is considered **medically necessary**.

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

- Percutaneous tibial nerve stimulation for all other indications not previously listed or if above criteria not met is considered **experimental or investigational** when any **ONE** or more of the following criteria are met:
1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
 3. Insufficient evidence to support improvement of the net health outcome; or
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
 5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to*:

- Neurogenic bladder dysfunction
- Fecal incontinence

- Subcutaneous tibial nerve stimulation delivered by an implantable peripheral neurostimulator system (e.g., eCoin®) for individuals with non-neurogenic urinary dysfunction including overactive bladder is considered **experimental or investigational** when any **ONE** or more of the following criteria are met:
1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
 3. Insufficient evidence to support improvement of the net health outcome; or
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives; or
 5. Insufficient evidence to support improvement outside the investigational setting.

Resources:

Literature reviewed 10/01/24. We do not include marketing materials, poster boards and non-published literature in our review.

1. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. *Obstet Gynecol.* Nov 2015;126(5):e66-e81. doi:10.1097/AOG.0000000000001148
2. Bharucha AE, Rao SSC, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. *Clin Gastroenterol Hepatol.* Dec 2017;15(12):1844-1854. doi:10.1016/j.cgh.2017.08.023

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

3. Boudaoud N, Binet A, Line A, et al. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. *J Pediatr Urol*. Jun 2015;11(3):138 e1-10. doi:10.1016/j.jpuro.2014.09.013
4. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. *Neurourol Urodyn*. Nov 2012;31(8):1206-16. doi:10.1002/nau.22251
5. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. *J Urol*. Jul 2024;212(1):11-20. doi:10.1097/JU.0000000000003985
6. Coolen RL, Groen J, Scheepe JR, Blok BFM. Transcutaneous Electrical Nerve Stimulation and Percutaneous Tibial Nerve Stimulation to Treat Idiopathic Nonobstructive Urinary Retention: A Systematic Review. *Eur Urol Focus*. Sep 2021;7(5):1184-1194. doi:10.1016/j.euf.2020.09.019
7. Edenfield AL, Amundsen CL, Wu JM, Levin PJ, Siddiqui NY. Posterior tibial nerve stimulation for the treatment of fecal incontinence: a systematic evidence review. *Obstet Gynecol Surv*. May 2015;70(5):329-41. doi:10.1097/OGX.0000000000000171
8. Eftekhar T, Teimoory N, Miri E, Nikfallah A, Naeimi M, Ghajarzadeh M. Posterior tibial nerve stimulation for treating neurologic bladder in women: a randomized clinical trial. *Acta Med Iran*. 2014;52(11):816-21.
9. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol*. Nov 2010;184(5):2001-6. doi:10.1016/j.juro.2010.06.113
10. Gaspard L, Tombal B, Opsomer RJ, Castille Y, Van Pesch V, Detrembleur C. [Physiotherapy and neurogenic lower urinary tract dysfunction in multiple sclerosis patients: a randomized controlled trial]. *Prog Urol*. Sep 2014;24(11):697-707. Kinesithérapie et symptômes du bas appareil urinaire chez des patients atteints de la sclérose en plaques : étude contrôlée randomisée. doi:10.1016/j.puro.2014.05.003
11. Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC Urol*. Nov 25 2013;13:61. doi:10.1186/1471-2490-13-61
12. George AT, Kalmar K, Sala S, et al. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. *Br J Surg*. Feb 2013;100(3):330-8. doi:10.1002/bjs.9000

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

13. Gilling P, Meffan P, Kaaki B, et al. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. *Urology*. Nov 2021;157:71-78. doi:10.1016/j.urology.2021.04.039
14. Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. *Gynecol Obstet Invest*. 2013;75(1):46-52. doi:10.1159/000343756
15. Ho FCS, He C, Yao HH, O'Connell HE, Gani J. Efficacy of sacral neuromodulation and percutaneous tibial nerve stimulation in the treatment of chronic nonobstructive urinary retention: A systematic review. *Neurourol Urodyn*. Jun 2021;40(5):1078-1088. doi:10.1002/nau.24694
16. Horrocks EJ, Chadi SA, Stevens NJ, Wexner SD, Knowles CH. Factors Associated With Efficacy of Percutaneous Tibial Nerve Stimulation for Fecal Incontinence, Based on Post-Hoc Analysis of Data From a Randomized Trial. *Clin Gastroenterol Hepatol*. Dec 2017;15(12):1915-1921 e2. doi:10.1016/j.cgh.2017.06.032
17. Horrocks EJ, Thin N, Thaha MA, Taylor SJ, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. *Br J Surg*. Apr 2014;101(5):457-68. doi:10.1002/bjs.9391
18. Kaaki B, English S, Gilling P, et al. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. *Female Pelvic Med Reconstr Surg*. May 1 2022;28(5):287-292. doi:10.1097/SPV.0000000000001105
19. Knowles CH, Horrocks EJ, Bremner SA, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. *Lancet*. Oct 24 2015;386(10004):1640-8. doi:10.1016/S0140-6736(15)60314-2
20. Leo CA, Thomas GP, Hodgkinson JD, et al. Randomized Pilot Study: Anal Inserts Versus Percutaneous Tibial Nerve Stimulation in Patients With Fecal Incontinence. *Dis Colon Rectum*. Apr 1 2021;64(4):466-474. doi:10.1097/DCR.0000000000001913
21. Levin PJ, Wu JM, Kawasaki A, Weidner AC, Amundsen CL. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. *Int Urogynecol J*. Nov 2012;23(11):1591-7. doi:10.1007/s00192-012-1712-4
22. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. *J Urol*. Sep 2019;202(3):558-563. doi:10.1097/JU.0000000000000309

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

23. Luo C, Wei D, Pang K, Mei L, Chen Y, Niu X. Is percutaneous tibial nerve stimulation (PTNS) effective for fecal incontinence (FI) in adults compared with sham electrical stimulation? A meta-analysis. *Tech Coloproctol*. Feb 24 2024;28(1):37. doi:10.1007/s10151-024-02910-w
24. MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. *J Urol*. May 2019;201(5):967-972. doi:10.1016/j.juro.2018.10.017
25. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol*. Jan 2010;183(1):234-40. doi:10.1016/j.juro.2009.08.160
26. Monteiro ES, de Carvalho LB, Fukujima MM, Lora MI, do Prado GF. Electrical stimulation of the posterior tibialis nerve improves symptoms of poststroke neurogenic overactive bladder in men: a randomized controlled trial. *Urology*. Sep 2014;84(3):509-14. doi:10.1016/j.urology.2014.05.031
27. Moosdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. *Neurourol Urodyn*. Mar 2013;32(3):206-14. doi:10.1002/nau.22296
28. Percutaneous tibial nerve stimulation for the treatment of voiding dysfunction TEC Assessments. 2013;Vol. 28:Tab 10. Located at: Blue Cross Blue Shield Association Technology Evaluation Center (TEC), Chicago, USA.
29. Perissinotto MC, D'Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. *J Wound Ostomy Continence Nurs*. Jan-Feb 2015;42(1):94-9. doi:10.1097/WON.0000000000000078
30. Peters K, Carrico D, Burks F. Validation of a sham for percutaneous tibial nerve stimulation (PTNS). *Neurourol Urodyn*. 2009;28(1):58-61. doi:10.1002/nau.20585
31. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *J Urol*. Apr 2010;183(4):1438-43. doi:10.1016/j.juro.2009.12.036
32. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol*. Jun 2013;189(6):2194-201. doi:10.1016/j.juro.2012.11.175
33. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*. Sep 2009;182(3):1055-61. doi:10.1016/j.juro.2009.05.045

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

34. Preyer O, Umek W, Laml T, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. *Eur J Obstet Gynecol Reprod Biol.* Aug 2015;191:51-6. doi:10.1016/j.ejogrb.2015.05.014
35. Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin(R) for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial. *J Urol.* Aug 2021;206(2):399-408. doi:10.1097/JU.0000000000001733
36. Sanagapalli S, Neilan L, Lo JYT, et al. Efficacy of Percutaneous Posterior Tibial Nerve Stimulation for the Management of Fecal Incontinence in Multiple Sclerosis: A Pilot Study. *Neuromodulation.* Oct 2018;21(7):682-687. doi:10.1111/ner.12764
37. Sarveazad A, Babahajian A, Amini N, Shamseddin J, Youseffard M. Posterior Tibial Nerve Stimulation in Fecal Incontinence: A Systematic Review and Meta-Analysis. *Basic Clin Neurosci.* Sep-Oct 2019;10(5):419-431. doi:10.32598/bcn.9.10.290
38. Schneider MP, Gross T, Bachmann LM, et al. Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. *Eur Urol.* Nov 2015;68(5):859-67. doi:10.1016/j.eururo.2015.07.001
39. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. *Int Urogynecol J.* Sep 2010;21(9):1065-70. doi:10.1007/s00192-010-1165-6
40. Shamliyan T, Wyman J, Kane RL. AHRQ Comparative Effectiveness Reviews. *Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness.* Agency for Healthcare Research and Quality (US); 2012.
41. Simillis C, Lal N, Qiu S, et al. Sacral nerve stimulation versus percutaneous tibial nerve stimulation for faecal incontinence: a systematic review and meta-analysis. *Int J Colorectal Dis.* May 2018;33(5):645-648. doi:10.1007/s00384-018-2976-z
42. Stewart F, Gameiro LF, El Dib R, Gameiro MO, Kapoor A, Amaro JL. Electrical stimulation with non-implanted electrodes for overactive bladder in adults. *Cochrane Database Syst Rev.* Dec 9 2016;12(12):CD010098. doi:10.1002/14651858.CD010098.pub4
43. Tan K, Wells CI, Dinning P, Bissett IP, O'Grady G. Placebo Response Rates in Electrical Nerve Stimulation Trials for Fecal Incontinence and Constipation: A Systematic Review and Meta-Analysis. *Neuromodulation.* Dec 2020;23(8):1108-1116. doi:10.1111/ner.13092
44. Thin NN, Taylor SJ, Bremner SA, et al. Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence. *Br J Surg.* Mar 2015;102(4):349-58. doi:10.1002/bjs.9695

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

**ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

45. Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature. *Eur Urol*. Mar 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002
46. Tutolo M, Ammirati E, Van der Aa F. What Is New in Neuromodulation for Overactive Bladder? *Eur Urol Focus*. Jan 2018;4(1):49-53. doi:10.1016/j.euf.2018.04.019
47. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): eCoinPeripheral Neurostimulator System (P200036). March 1, 2022. Accessed June 20, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036B.pdf
48. Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. *Int Braz J Urol*. Jan-Feb 2018;44(1):102-108. doi:10.1590/S1677-5538.IBJU.2016.0611
49. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. *Gynecol Obstet Invest*. 2013;75(4):230-4. doi:10.1159/000350216
50. Wang M, Jian Z, Ma Y, Jin X, Li H, Wang K. Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. *Int Urogynecol J*. Dec 2020;31(12):2457-2471. doi:10.1007/s00192-020-04429-8
51. Welk B, McKibbin M. A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. *Can Urol Assoc J*. Jul 2020;14(7):E297-E303. doi:10.5489/cuaj.6142
52. Xiong SC, Peng L, Hu X, Shao YX, Wu K, Li X. Effectiveness and safety of tibial nerve stimulation versus anticholinergic drugs for the treatment of overactive bladder syndrome: a meta-analysis. *Ann Palliat Med*. Jun 2021;10(6):6287-6296. doi:10.21037/apm-21-339
53. Zonic-Imamovic M, Imamovic S, Cickusic A, Delalic A, Hodzic R, Imamovic M. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. *Acta Med Acad*. Dec 2019;48(3):271-277. doi:10.5644/ama2006-124.267
54. Zyczynski HM, Richter HE, Sung VW, et al. Percutaneous Tibial Nerve Stimulation vs Sham Stimulation for Fecal Incontinence in Women: Neuromodulation for Accidental Bowel Leakage Randomized Clinical Trial. *Am J Gastroenterol*. Apr 1 2022;117(4):654-667. doi:10.14309/ajg.0000000000001605



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Coding:

CPT: 0587T, 0588T, 0589T, 0590T, 0816T, 0818T, 64566, 64999

CPT copyright 2023 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

<u>History:</u>	<u>Date:</u>	<u>Activity:</u>
Medical Policy Panel	10/01/24	Review with revisions
Medical Director (Dr. Raja)	09/05/24	Review with revisions
Medical Policy Panel	10/03/23	Approved guideline

Policy Revisions:

10/01/24	Updated:	Description section, Resources section
10/01/24	Added:	CPT codes: 0816T, 0818T



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: SURGERY

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nilínígíí Blue Cross Blue Shield of Arizona haada yit'éego bina'idííkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yina'idííkidgo beehaz'áanii hólo díí t'áa hazaadk'ehjí háká a'doowolgo bee haz'á doo baqah ilínígóó. Ata' halne'ígíí kojí' bich'í' hodíilnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:

إن كان لديك أو لدى شخص تساعد أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم اتصل بـ 877-475-4799.

**EVIDENCE-BASED CRITERIA
SECTION: SURGERY**

ORIGINAL EFFECTIVE DATE: 10/03/23
LAST REVIEW DATE: 10/01/24
CURRENT EFFECTIVE DATE: 10/01/24
LAST CRITERIA REVISION DATE: 10/03/23
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2025

PERCUTANEOUS AND SUBCUTANEOUS TIBIAL NERVE STIMULATION

Multi-Language Interpreter Services:

Tagalog: Kung ikaw, o ang iyong tinutulungan, ay may mga katanungan tungkol sa Blue Cross Blue Shield of Arizona, may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika ng walang gastos. Upang makausap ang isang tagasalin, tumawag sa 877-475-4799.

Korean: 만약 귀하 또는 귀하가 돕고 있는 어떤 사람이 Blue Cross Blue Shield of Arizona 에 관해서 질문이 있다면 귀하는 그러한 도움과 정보를 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 그렇게 통역사와 얘기하기 위해서는 877-475-4799 로 전화하십시오.

French: Si vous, ou quelqu'un que vous êtes en train d'aider, a des questions à propos de Blue Cross Blue Shield of Arizona, vous avez le droit d'obtenir de l'aide et l'information dans votre langue à aucun coût. Pour parler à un interprète, appelez 877-475-4799.

German: Falls Sie oder jemand, dem Sie helfen, Fragen zum Blue Cross Blue Shield of Arizona haben, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer 877-475-4799 an.

Russian: Если у вас или лица, которому вы помогаете, имеются вопросы по поводу Blue Cross Blue Shield of Arizona, то вы имеете право на бесплатное получение помощи и информации на вашем языке. Для разговора с переводчиком позвоните по телефону 877-475-4799.

Japanese: ご本人様、またはお客様の身の回りの方でも、Blue Cross Blue Shield of Arizona についてご質問がございましたら、ご希望の言語でサポートを受けたり、情報を入手したりすることができます。料金はかかりません。通訳とお話される場合、877-475-4799 までお電話ください。

Farsi:

اگر شما، یا کسی که شما به او کمک میکنید، سوال در مورد Blue Cross Blue Shield of Arizona، داشته باشید حق این را دارید که کمک و اطلاعات به زبان خود را به طور رایگان دریافت نمایید 877-475-4799 [تماس حاصل نمایید].

Assyrian:

Blue Cross Blue Shield of Arizona, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, nazovite 877-475-4799.

Serbo-Croatian: Ukoliko Vi ili neko kome Vi pomažete ima pitanje o Blue Cross Blue Shield of Arizona, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, nazovite 877-475-4799.

Thai: หากคุณ หรือคนที่คุณกำลังช่วยเหลือคำถามเกี่ยวกับ Blue Cross Blue Shield of Arizona คุณมีสิทธิที่จะได้รับความช่วยเหลือและข้อมูลในภาษา ของคุณได้โดยไม่มีค่าใช้จ่าย โปรดสอบถาม โทร 877-475-4799